Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted vs Liberal Blood Pressure Management and Remimazolam vs Propofol in OPCAB
NCT07787364Not yet recruiting
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Oct 2026
- Primary completion
- Dec 2027
01
Overview
Randomised trial of remimazolam in coronary artery disease (CAD) (4 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Incidence of the 30-Day Composite of Postoperative Complications or All-Cause Mortality. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT07787364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07787364.